Recital 8, Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009…

In forcesince 6 May 2009cited 17×

Therefore, the provision of a supplementary protection certificate granted, under the same conditions, by each of the Member States at the request of the holder of a national or European patent relating to a medicinal product for which marketing authorisation has been granted is necessary. A regulation is therefore the most appropriate legal instrument.

The 10 that are cited most themselves, of 17.

  • Judgment of the Court (Fourth Chamber) of 24 November 2011. Medeva BV v Comptroller General of Patents, Designs and Trade Marks.Decision

    Recital 1 and recitals 4 to 10 in the preamble to Regulation No 469/2009 are worded as follows: ‘(1) Council Regulation (EEC) No 1768/92 of 18 June 1992 concerning the creation of a supplementary protection certificate for medicinal …

    24 Nov 2011 · 62010CJ0322

  • Judgment of the Court (Fourth Chamber), 19 July 2012. Neurim Pharmaceuticals (1991) Ltd v Comptroller-General of Patents.Decision

    Recitals 1 and 4 to 10 of the SPC Regulation read as follows: Council Regulation (EEC) No 1768/92 … has been substantially amended several times. In the interests of clarity and rationality the said Regulation should be codified. ... At …

    19 Jul 2012 · 62011CJ0130

  • Judgment of the Court (Fourth Chamber) of 24 November 2011. Georgetown University and Others v Comptroller General of Patents, Designs and TDecision

    Recital 1 and recitals 4 to 10 in the preamble to Regulation No 469/2009 are worded as follows: Council Regulation (EEC) No 1768/92 of 18 June 1992 concerning the creation of a supplementary protection certificate for medicinal products …

    24 Nov 2011 · 62010CJ0422

  • Judgment of the Court (Fourth Chamber) of 21 March 2019. Abraxis Bioscience LLC v Comptroller General of Patents.Decision

    Recitals 3 to 5 and 7 to 10 of Regulation No 469/2009 state as follows: Medicinal products, especially those that are the result of long, costly research will not continue to be developed in the [European Union] and in Europe unless they …

    21 Mar 2019 · 62017CJ0443

  • Judgment of the Court (Grand Chamber) of 9 July 2020. Santen SAS v Directeur général de l’Institut national de la propriété industrielle.Decision

    Recitals 3, 4 and 7 to 10 of Regulation No 469/2009 state: Medicinal products, especially those that are the result of long, costly research will not continue to be developed in the Community and in Europe unless they are covered by …

    9 Jul 2020 · 62018CJ0673

  • Order of the Court (Fourth Chamber) of 25 November 2011. University of Queensland and CSL Ltd v Comptroller General of Patents, Designs and Decision

    Recital 1 and recitals 4 to 10 in the preamble to Regulation No 469/2009 are worded as follows: ‘(1) Council Regulation (EEC) No 1768/92 of 18 June 1992 concerning the creation of a supplementary protection certificate for medicinal …

    25 Nov 2011 · 62010CO0630

  • Judgment of the Court (Eighth Chamber) of 6 October 2015. Seattle Genetics Inc. v Österreichisches Patentamt.Decision

    It should be noted in that regard that, as is apparent from recitals 7 and 8 in the preamble thereto, Regulation No 469/2009 establishes a uniform solution at European Union level by creating an SPC which may be obtained by the holder of a …

    6 Oct 2015 · 62014CJ0471

  • Order of the Court (Eighth Chamber) of 14 November 2013. Astrazeneca AB v Comptroller General of Patents, Designs and Trade Marks.Decision

    Thus, under Article 13 of Regulation No 469/2009, in conjunction with Annex II to the EEA Agreement, as amended by Annex 2 to Decision No 1/95, an MA issued by the Swiss authorities and automatically recognised in Liechtenstein in the …

    14 Nov 2013 · 62012CO0617

  • Opinion of Advocate General Saugmandsgaard Øe delivered on 13 December 2018. Abraxis Bioscience LLC v Comptroller General of Patents.Decision

    According to recitals 3, 4, 5 and 9 of Regulation No 469/2009, the SPC regime has the purpose of compensating for the lack of protection conferred by a patent with respect to covering the investment put into research concerning new …

    13 Dec 2018 · 62017CC0443

  • Opinion of Advocate General Jääskinen delivered on 10 September 2015. Seattle Genetics Inc. v Österreichisches Patentamt.Decision

    Recitals 4, 8 and 9 in the preamble to Regulation No 469/2009 are worded as follows: At the moment, the period that elapses between the filing of an application for a patent for a new medicinal product and authorisation to place the …

    10 Sep 2015 · 62014CC0471